<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css" integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw==" crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CDN -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Main CSS -->
    <link rel="stylesheet" href="css/style.css">

</head>

<body>

    <div class="fixedHeight">
        <div class="right_shape">
            <a href="../page38/index.html" class="cross_icon_close">
                <img src="img/cross_icon.svg" alt="">
            </a>
            <img src="img/right_silver_shape.png" style="zoom: .5;" alt="">
        </div>
        <div class="container_xxl container-xxl py-4 z_index9">
            <div>
                <div class="w_heading border-0 pb-5">
                    <h3 class="txt_orange GothamMedium">US-MM6: feasibility of long-term proteasome <br> inhibition in multiple myeloma by in-class transition from bortezomib to ixazomib<sup class="h5">1</sup></h3>
                </div>
                <div class="w-50">
                    <div class="p19_table_row_border_t">
                        <h4 class="GothamMedium fst-italic txt_blue mb-4 pt-2">Study Design</h4>
                    </div>
                </div>
                <h5 class="page21_blue mb-2 w-75 pe-2 bold">US MM-6 is an ongoing US community–based, Real-world, open-label, single-arm, <br>
                    phase 4 study in patients with newly diagnosed multiple myeloma who are transplant <br>
                    ineligible or for whom transplant would be delayed ≥24 months and who are receiving <br>
                    first-line VELCADE-based induction<sup>1</sup></h5>

                <div class="w-75 py-3 d-flex flex-wrap">
                    <div class="w-50 txt_silver GothamLight pe-3 fs-14 d-flex"><div class="me-1"><img src="img/list_orange_icon.svg" alt=""></div> <div>This study included Real-world patients who are often underrepresented in clinical trials because of eligibility criteria: 44% of patients were aged ≥75 years, 15% were Black or African American, 10% were Hispanic/Latino, 29% had creatinine clearance &lt;60 mL/min, and 99% had any concurrent medical condition<sup>1</sup></div></div>

                    <div class="w-50">
                        <div class="txt_silver GothamLight pe-2 d-flex mb-2 fs-14"><div class="me-1"><img src="img/list_orange_icon.svg" alt=""></div> <div>85% of patients received VRD, 13% received VCD, and 2% received other (VD, VR) induction regimens at the time of in-class transition to the Ixazomib (NINLARO) regimen<sup>1</sup></div></div>

                        <div class="txt_silver GothamLight d-flex pe-2 fs-14"><div class="me-1"><img src="img/list_orange_icon.svg" alt=""></div> <div>The primary endpoint is 2-year PFS, from the first administration of the Ixazomib (NINLARO) regimen<sup>1</sup></div></div>
                    </div>
                </div>

                <div class="page_39_div pt-2 pb-3" style="max-width: 1100px;">
                    <div class="page_39_div_1">
                        <p class="mb-0 GothamMedium dark_secondary text-center fs-11">Patients receive
                            3 cycles of
                            VELCADE-based
                            induction
                            (per regimens
                            listed in NCCN
                            guidelines)</p>
                    </div>
                    <div class="page_39_div_2">
                        <p class="mb-2 GothamMedium dark_secondary text-center fs-11">
                            No evidence <br> of disease progression</p>
                            <img width="26" src="img/right-128.svg" alt="">
                    </div>
                    <div class="page_39_div_3">
                        <p class="mb-2 GothamMedium dark_secondary fs-11">
                            Eligibility criteria:</p>
                            <ul class="ps-4 mb-0 dark_secondary GothamMedium fs-11">
                                <li>ECOG and/or other performance status of 0 to 2</li>
                                <li> No grade ≥2 PN or grade 1 PN with pain</li>
                            </ul>
                    </div>
                    <div class="page_39_div_4">
                        <img src="img/right-128.svg" alt="">
                    </div>
                    <div class="page_39_div_5">
                        <p class="GothamBold mb-0 fs-12">Maximum of 39 cycles or until disease progression or toxicity</p>
                        <div>
                            <p class="fs-10 GothamMedium text-center dark_secondary">Ixazomib <br> (NINLARO)</p>
                            <img class="d-block mx-auto mb-2" src="img/capsule_orange.svg" alt="">
                            <p class="GothamBook text-center dark_secondary fs-10 mb-0"><strong>4 mg</strong> <br> DAYS 1, 8, AND 15</p>
                        </div>
                        <i class="align-self-center fas fa-plus"></i>
                        <div>
                            <p class="fs-10 GothamMedium text-center dark_secondary">Lenalidomide</p>
                            <img class="d-block mx-auto mb-2" src="img/capsule_silver.svg" alt="">
                            <p class="GothamBook text-center dark_secondary fs-10 mb-0"><strong>25 mg</strong> <br> DAYS 1–21</p>
                        </div>
                        <i class="align-self-center fas fa-plus"></i>
                        <div>
                            <p class="fs-10 GothamMedium text-center dark_secondary">Dexamethasone</p>
                            <img class="d-block mx-auto mb-3" src="img/capsule_blue.svg" alt="">
                            <p class="GothamBook text-center dark_secondary fs-10 mb-0"><strong>40 mg</strong> <br> DAYS 1, 8, 15, AND 22</p>
                        </div>
                    </div>
                </div>

                <div class="py-4">
                    <div class="GothamBook txt_silver fs-11"><span class="GothamBold">Study limitation:</span> study is an open-label trial lacking a comparator arm, which may limit interpretation of the results</div>
                </div>
            </div>
        </div>
        <div style="height: 60px;"></div>
        <div class="footer_page1 bg-transparent">
            <div class="container_xxl container-xxl">
                <div class="footer_inner1 footer_inner2 w-100">
                    <p class="GothamLight fs_12">ECOG = Eastern Cooperative Oncology Group; NCCN = National Comprehensive Cancer Network; PN = peripheral neuropathy; US = United States; VCD = bortezomib, cyclophosphamide, dexamethasone; <br>
                        VD = bortezomib, dexamethasone; VR = bortezomib, lenalidomide; VRD = bortezomib, lenalidomide, dexamethasone.</p>
                </div>
            </div>
            <div class="footer_inner_nav1 bg-transparent footer_inner_nav1_modified_reff" style="z-index: 10;">
                <ul class="mb-1 me-1">
                    <li>
                        <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                    </li>
                    <li>
                        <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                    </li>
                    <li>
                        <a href="../page40/index.html" class="text-uppercase">ref</a>
                    </li>
                </ul>
            </div>
        </div>
    </div>

</body>

</html>